VISCHER advised Polyneuron in its Series A Financing extension to CHF 36.5m

Polyneuron Pharmaceuticals, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by autoimmune diseases, extended its Series A by CHF 14m bringing the total to CHF 36.5m. HBM Healthcare Investments joins as additional investor to lead investor Sofinnova Partners and New Enterprise Associates.

VISCHER advises Polyneuron with a team led by Matthias Staehelin (Partner – pictured) with Moritz Jäggy (Managing Associate), both Corporate.

VISCHER advised Polyneuron in its Series A Financing extension to CHF 36.5m

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram